Journal
FRONTIERS IN PSYCHIATRY
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fpsyt.2018.00554
Keywords
schizophrenia; mismatch negativity; biomarker; clinical trial; cognitive impairment
Categories
Funding
- Sidney R. Baer, Jr. Foundation
- Brain and Behavior Research Foundation
- Department of Veteran Affairs VISN-22 Mental Illness Research, Education, and Clinical Center (MIRECC)
Ask authors/readers for more resources
Due to advances over the last several decades, many fields of medicine are moving toward a precision medicine approach where treatments are tailored to nuanced patient factors. While in some disciplines these innovations are commonplace leading to unique biomarker-guided experimental medicine trials, there are no such analogs in psychiatry. In this brief review, we will overview two unique biomarker-guided trial designs for future use in psychiatry: basket and umbrella trials. We will illustrate how such trials could be useful in psychiatry using schizophrenia as a candidate illness, the EEG measure mismatch negativity as the candidate biomarker, and cognitive impairment as the target disease dimension.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available